Adicet Bio (ACET) Hisse Özeti

ACET temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $0 )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Anlamlı bir piyasa değeri yok ( $88M )

ACET Community Fair Values

Create Narrative

See what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Adicet Bio, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Adicet Bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$7.68
52 Haftanın En Yüksek Seviyesi	US$17.44
52 Haftanın En Düşük Seviyesi	US$6.01
Beta	1.51
1 Aylık Değişim	-3.03%
3 Aylık Değişim	11.14%
1 Yıllık Değişim	-38.24%
3 Yıllık Değişim	-92.36%
5 Yıllık Değişim	-96.68%
Halka arzdan bu yana değişim	-96.88%

Son Haberler & Güncellemeler

Recent updates

Analiz Makalesi • May 23

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Feb 06

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Jul 12

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Seeking Alpha • May 23

Adicet Bio: Microcap With A High Risk To Reward Ratio

Summary Adicet Bio is a biotech company focused on developing off-the-shelf cell therapies for cancer and autoimmune diseases. They are currently conducting a phase 1 trial for their pilot cell therapy, ADI-001, targeting B-cell non-Hodgkin's lymphomas. Adicet has a strong financial position with $247.6 million in cash and equivalents, providing them with 8-9 quarters of cash on hand. Read the full article on Seeking Alpha

Analiz Makalesi • Feb 01

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Key Insights Adicet Bio's estimated fair value is US$5.96 based on 2 Stage Free Cash Flow to Equity Adicet Bio's...

Analiz Makalesi • Dec 07

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Aug 07

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Apr 20

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analiz Makalesi • Dec 20

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Seeking Alpha • Oct 17

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Healthcare and life sciences focused investment management firm RA Capital has taken a passive stake in clinical-stage cancer therapies biotech Adicet Bio (NASDAQ:ACET). RA Capital Management LP, managing partners Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund LP each took a 5.5% passive stake in ACET, the investment management firm disclosed in a regulatory filing on Monday. RA Capital Management, Kolchinsky, Shah and the Fund own around 2.4M shares of ACET each. ACET discovers and develops allogeneic gamma delta T-cell therapies for cancer. The company is advancing a pipeline of what it calls "off-the-shelf" gamma delta T-cells. ACET stock was 6.7% lower to $15.50 after hours. It earlier closed -1.9% at $16.29.

Analiz Makalesi • Oct 04

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Does the October share price for Adicet Bio, Inc. ( NASDAQ:ACET ) reflect what it's really worth? Today, we will...

Analiz Makalesi • Aug 16

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

The latest analyst coverage could presage a bad day for Adicet Bio, Inc. ( NASDAQ:ACET ), with the analysts making...

Seeking Alpha • Jul 22

Adicet Bio: A First Take

Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate. An investment analysis follows in the paragraphs below. Don't live the same year 75 times and call it a life."― Robin S. Sharma Today, we put Adicet Bio, Inc. (ACET) in the spotlight for the first time. The company is on the vanguard of the next wave of CAR-T development. Unfortunately, the lousy sentiment on biotech over the past few years and its slow pace of development has put the shares firmly in Busted IPO territory. A quick analysis on this name follows below. Seeking Alpha Company Overview: Adicet Bio is a clinical-stage biotech concern based out of Boston. The company is focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The stock currently trades just over $17.00 a share and sports an approximate market capitalization of $700 million. The company's developmental platform is based on allogeneic gamma delta T cells which have several advantages over the Alpha T cells which spawned the first generation of CAR T therapies. These advantages include durability and safety. July Company Presentation These T cells do a better job of specifically targeting cancer cells while avoiding harm to normal tissues and have many potential uses in oncology, particularly solid tumors. Adicet's technology platform can activate and expand gamma delta cells (see process above). July Company Presentation Adicet has many candidates in its pipeline as can be seen from the chart below. July Company Presentation The firm's pipeline is very early stage at this point and will build out as the company plans to submit one new IND every 12-18 months. The furthest along of these efforts is ADI-001. This is an allogeneic CD20 gamma delta 1 CAR T therapy. ADI-001 is designed to target malignant B cells by leveraging the innate and adaptive receptors found naturally on gamma delta T cells with the added benefit of an engineered anti CD20 CAR. The candidate has shown solid promise in an ongoing study to treat relapsed or refractory B-cell Non-Hodgkin's lymphoma ((NHL)). This candidate garnered Fast Track Designation for this indication from the FDA in April of this year. July Company Presentation The next step for management is to engage the FDA around a pivotal-intent single arm clinical trial that hopefully results in an accelerated approval for ADI-001, provided the data meets/exceeds all criteria. Here are some of the other milestones the company has planned over the next year or so. July Company Presentation Analyst Commentary & Balance Sheet: Since March, eight analyst firms including Jefferies and BTIG have reissued or assigned Buy ratings to the stock. Price targets proffered range from $21.00 to $35.00 a share. The stock has its share of bears given that one out of every four shares outstanding are currently held short. Insiders have been frequent but small sellers of the stock throughout 2022, disposing of just less than $1 million worth of shares in aggregate so far this year. There has been no insider purchases in the equity so far in 2022. The company ended the first quarter with just over $275 million of cash and marketable securities on its balance sheet. Management has stated that is adequate to fund all operations into the second half of 2024. Verdict: The problem with Adicet and all CAR-T concerns is the pace of development is always slow. This is especially true with a pipeline that is very early stage. In a bull market, a small "watch item" position in ACET might be warranted as its technology platform appears intriguing.

Analiz Makalesi • Jul 07

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • May 15

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

There's been a major selloff in Adicet Bio, Inc. ( NASDAQ:ACET ) shares in the week since it released its first-quarter...

Analiz Makalesi • Mar 18

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Feb 09

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

The company’s platform is based on gamma delta 1 T cells, which have been major investor attention recently. The next data update from the above ADI-001 FIH study is expected in mid this year (likely at the EHA conference from June 9-12 (the next key catalyst). Long-term, this is a 10-20x opportunity in a 2-5 years timeframe if not acquired by then.

Hissedar Getirileri

	ACET	US Biotechs	US Pazar
7D	-10.2%	-1.6%	-0.9%
1Y	-38.2%	34.4%	24.4%

Getiri vs. Endüstri: ACET geçen yıl % 34.4 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ACET geçen yıl % 24.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ACET's price volatile compared to industry and market?
ACET volatility
ACET Average Weekly Movement	9.9%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ACET son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ACET 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2014	102	Chen Schor	www.adicetbio.com

Klinik aşamada bir biyoteknoloji şirketi olan Adicet Bio, Inc. Amerika Birleşik Devletleri'nde otoimmün hastalıklar ve kanser için allojenik gama delta T hücre tedavileri keşfetmekte ve geliştirmektedir. Şirketin öncü ürün adayı olan prulacabtagene leucel (prula-cel), otoimmün hastalıkların potansiyel tedavisi için CD20'yi hedefleyen bir CAR ifade eden allojenik bir gama delta T hücre tedavisidir. Ayrıca, prostat spesifik membran antijenini hedefleyen genle düzenlenmiş ve zırhlı bir klinik aday olan ADI-212'yi geliştirmektedir.

Adicet Bio, Inc. Temel Bilgiler Özeti

Adicet Bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ACET temel i̇stati̇sti̇kler
Piyasa değeri	US$88.31m
Kazançlar(TTM)	-US$108.83m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.7x

F/K Oranı

ACET aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ACET gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$108.83m
Kazançlar	-US$108.83m

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-10.36
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

ACET uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/15 13:33
Gün Sonu Hisse Fiyatı	2026/05/15 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Adicet Bio, Inc. 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Justin Zelin	B. Riley Securities, Inc.
John Newman	Canaccord Genuity
Yatin Suneja	Guggenheim Securities, LLC

Adicet Bio (ACET) Hisse Özeti

Risk Analizi

Adicet Bio, Inc. Rakipler

KALA BIO

XBiotech

Genelux

Gain Therapeutics

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Adicet Bio, Inc., Annual General Meeting, Jun 17, 2026

Adicet Bio, Inc. Announces That Enrollment in Its Prulacabtagene Leucel (Prula-Cel, Formerly Adi-001) Phase 1 Program in Autoimmune Diseases Has Doubled to over 20 Patients

Adicet Bio, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis

Adicet Bio, Inc. Receives Notice of Nasdaq Listing Transfer and Extension to Regain Bid Price Compliance

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Adicet Bio, Inc. Announces First Systemic Sclerosis (Ssc) Patient Dosed in Ongoing Phase 1 Clinical Trial of Adi-001 in Autoimmune Diseases

Recent updates

Adicet Bio, Inc., Annual General Meeting, Jun 17, 2026

Adicet Bio, Inc. Announces That Enrollment in Its Prulacabtagene Leucel (Prula-Cel, Formerly Adi-001) Phase 1 Program in Autoimmune Diseases Has Doubled to over 20 Patients

Adicet Bio, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis

Adicet Bio, Inc. Receives Notice of Nasdaq Listing Transfer and Extension to Regain Bid Price Compliance

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Adicet Bio, Inc. Announces First Systemic Sclerosis (Ssc) Patient Dosed in Ongoing Phase 1 Clinical Trial of Adi-001 in Autoimmune Diseases

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio, Inc. to Report Q1, 2025 Results on May 06, 2025

Adicet Bio, Inc., Annual General Meeting, Jun 11, 2025

Adicet Bio, Inc. Announces Resignation of Carl L. Gordon as Board Member, Effective April 17, 2025

Adicet Bio Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule

Adicet Bio, Inc. Plans to Continue Advancing Gamma Delta 1 Car T Cell Therapy Programs

Adicet Bio, Inc. Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis

Adicet Bio, Inc. Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Adicet Bio, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio, Inc. Announces Executive Changes

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio: Microcap With A High Risk To Reward Ratio

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has filed a Follow-on Equity Offering.

Price target decreased by 18% to US$12.80

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Price target decreased by 15% to US$18.29

New minor risk - Market cap size

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Price target decreased by 14% to US$23.29

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 180%, EPS downgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Chief Technology Officer notifies of intention to sell stock

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Consensus forecasts updated

CEO, President & Director notifies of intention to sell stock

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Now 23% undervalued after recent price drop

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term